Targeted Immunotherapy for KRAS-Driven Cancers
Application
Targeted immunotherapy and companion biosensing approach for cancers harboring the KRASG12V mutation.
Key Benefits
- First-in-class therapeutic strategy specifically designed for KRASG12V-positive cancers.
- Addresses a significant unmet need in oncology where no approved KRASG12V-targeted therapies currently exist.
- Restores the body’s natural immune response to improve tumor cell elimination.
Market Summary
KRAS mutations are among the most common cancer-driving alterations and are found across major tumor types, including lung, pancreatic, colorectal, and thyroid cancers. The KRASG12V mutation alone represents 85% of all cancer mutations, yet there are currently no approved drugs that directly address this mutation. With growing interest and investment in precision oncology and immunotherapy, there is a strong unmet need for mutation-specific therapies that can expand treatment options and improve patient outcomes for KRAS-driven cancers.
Technical Summary
Emory researchers have identified a previously unexploited interaction involving the KRASG12V mutant protein that plays a role in suppressing the immune system’s ability to attack cancer cells. By disrupting this interaction using a proprietary peptide-based inhibitor, the technology restores immune signaling and enhances cancel cell killing in KRASG12V-positive tumors. This approach introduces a new therapeutic target and modality for KRAS-mutant cancers and provides a foundation for developing next-generation immunotherapies with strong differentiation from existing oncology pipelines.
Development Stage
In vitro studies completed with co-culture data showing interaction between KRASG12V and JAK1.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
| Nationalized PCT - Foreign |
Canada |
3,142,404 |
|
12/1/2021 |
|
Pending |
| Nationalized PCT - United States |
United States |
17/617,269 |
|
12/7/2021 |
|
Pending |
| Nationalized PCT - Foreign |
EP |
20818184.2 |
|
12/16/2021 |
|
Pending |
|
|
